Approval Clears Way For Evolocumab To Blaze Japan PCSK9 Trail
This article was originally published in PharmAsia News
Executive Summary
Following a positive recommendation late last year, Japan has now issued a formal regulatory approval to Amgen Astellas’s evolocumab, which will blaze a trail as the first PCSK9-targeting biologic to be commercialized in the country.